ArticleBMC microbiology2022
An antimicrobial peptide specifically active against Listeria monocytogenes is secreted by Bacillus pumilus SF214.
Article in BMC microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Systematic Categorization and Functional Diversity of Secondary Metabolites from Bacillus spp.: A Review.Probiotics and antimicrobial proteins · 2026Review
- Article
- Research on the application of a high-throughput fully automated bacterial growth curve monitor for screening natural antibacterial compounds.BMC microbiology · 2025Article
- StreamliningAntibiotics (Basel, Switzerland) · 2025Article
- Diversity of culturable bacterial isolates and their potential as antimicrobial against human pathogens from Afar region, Ethiopia.Microbiology spectrum · 2024Article
- Antibacterial peptides from black soldier fly (Hermetia illucens) larvae: mode of action and characterization.Scientific reports · 2024Article
- Metagenomic nanopore sequencing for exploring the nature of antimicrobial metabolites of Bacillus haynesii.AMB Express · 2024Article
- Study of the Antimicrobial Activity of the Human Peptide SQQ30 against Pathogenic Bacteria.Antibiotics (Basel, Switzerland) · 2024Article
- The ProbioticMicroorganisms · 2023Article
- Probiotics as an Alternative to Antibiotics: Genomic and Physiological Characterization of Aerobic Spore Formers from the Human Intestine.Microorganisms · 2023Article
- Diversity of Culturable Bacteria from Endemic Medicinal Plants of the Highlands of the Province of Parinacota, Chile.Biology · 2023Article
- Biocontrol of fungal phytopathogens byFrontiers in microbiology · 2023Review
- Comparative Genomics and Physiological Characterization of Two Aerobic Spore Formers Isolated from Human Ileal Samples.International journal of molecular sciences · 2022Article
- Modulation of intestinal epithelial cell proliferation and apoptosis by Lactobacillus gasseri SF1183.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMembers of the Bacillus genus produce a large variety of antimicrobial peptides including linear or cyclic lipopeptides and thiopeptides, that often have a broad spectrum of action against Gram-positive and Gram-negative bacteria. We have recently reported that SF214, a marine isolated strain of Bacillus pumilus, produces two different antimicrobials specifically active against either Staphylococcus aureus or Listeria monocytogenes. The anti-Staphylococcus molecule has been previously characterized as a pumilacidin, a nonribosomally synthesized lipopetide composed of a mixture of cyclic heptapeptides linked to fatty acids of variable length.
resultsOur analysis on the anti-Listeria molecule of B. pumilus SF214 indicated that it is a peptide slightly smaller than 10 kDa, produced during the exponential phase of growth, stable at a wide range of pH conditions and resistant to various chemical treatments. The peptide showed a lytic activity against growing but not resting cells of Listeria monocytogenes and appeared extremely specific being inactive also against L. innocua, a close relative of L. monocytogenes.
conclusionsThese findings indicate that the B. pumilus peptide is unusual with respect to other antimicrobials both for its time of synthesis and secretion and for its strict specificity against L. monocytogenes. Such specificity, together with its stability, propose this new antimicrobial as a tool for potential biotechnological applications in the fight against the dangerous food-borne pathogen L. monocytogenes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.